Health benefits of Bitter Melon (Momordica charantia)

Bioactive Foods in Promoting Health

Volumn , Issue , 2010, Pages 525-549

  Lucas, Edralin A ^a   Dumancas, Gerard G ^a   Smith, Brenda J ^a   Clarke, Stephen L ^a   Arjmandi, Bahram H ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Bitter melon; Dyslipidemia; Mamordica charantia, diabetes

Indexed keywords

EID: 84882468760     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374628-3.00035-9     Document Type: Chapter

References (123)

1. Grover J.K., Yadav S.P. Pharmacological actions and potential uses of Momordica charantia: A review. Journal of Ethnopharmacology 2004, 93:123-132.
2. Yang S., Walters T. Ethnobotany and the economic role of cucurbitaceae of China. Economic Botany 1992, 46:349-367.
3. (2008). USDA National Nutrient Database for Standard Reference, Release 21.. http://www.nal.usda.gov/fnic/foodcomp/cgi-bin/list_nut_edit.pl.
4. Yen G.C., Hwang L.S. Lycopene from the seeds of ripe bitter melon (Momordica charantia) as a potential red food colorant. II. Storage stability, preparation of powdered lycopene and food applications. Journal of Chinese Agricultural Chemical Society 1985, 23:151-161.
5. Okabe H., Miyahara Y., Yamauchi T. Studies on the constituents of Momordica charantia L. IV. Characterization of the new cucurbitacin glycosides of the immature fruits. (2). Structures of the bitter glycosides, momordicosides K and L. Chemical and Pharmaceutical Bulletin (Tokyo) 1982, 30:4334-4340.
6. Yasuda M., Iwamoto M., Okabe H., Yamauchi T. Structures of momordicines I, II, and III, the bitter principles in the leaves and vines of Momordica charantia L. Chemical and Pharmaceutical Bulletin (Tokyo) 1984, 32:2044-2047.
7. Khanna P., Jain S.C., Panagariya A., Dixit V.P. Hypoglycemic activity of polypeptide-p from a plant source. Journal of Natural Products 1981, 44:648-655.
8. Lotlikar M.M., Rajarama Rao M.R. Pharmacology of a hypoglycaemic principle isolated from fruit of Momordica charantia Linn. Industrial Journal of Pharmacology 1966, 28:129-133.
9. Matsuda H., Li Y., Murakami T., Matsumura N., Yamahara J., Yoshikawa M. Antidiabetic principles of natural medicines. III. Structure-related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Chemical and Pharmaceutical Bulletin (Tokyo) 1998, 46:1399-1403.
10. Murakami T., Emoto A., Matsuda H., Yoshikawa M. Medicinal foodstuffs. XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese Momordica charantia L. Chemical and Pharmaceutical Bulletin (Tokyo) 2001, 49:54-63.
11. Harinantenaina L., Tanaka M., Takaoka S., Oda M., Mogami O., Uchida M., Asakawa Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chemical and Pharmaceutical Bulletin (Tokyo) 2006, 54:1017-1021.
12. Miyahara Y., Okabe H., Yamauchi T. Studies on the constituents of Momordica charantia L. II. Isolation and characterization of minor seed glycosides, Momordicosides C, D, and E. Chemical and Pharmaceutical Bulletin (Tokyo) 1981, 29:1561-1566.
13. Okabe H., Miyahara Y., Yamauchi T., Miyahara K., Kawasaki T. Studies on the constituents of Momordica charantia L. I. Isolation and characterization of momordicosides A and B, glycosides of a penta-hydroxy-cucurbitane triterpene. Chemical and Pharmaceutical Bulletin (Tokyo) 1980, 28:2753-2762.
14. Chang C.I., Chen C.R., Liao Y.W., Cheng H.L., Chen Y.C., Chou C.H. Cucurbitane-type triterpenoids from Momordica charantia. Journal of Natural Products 2006, 69:1168-1171.
15. Cheng H.L., Huang H.K., Chang C.I., Tsai C.P., Chou C.H. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. Journal of Agricultural and Food Chemistry 2008, 56:6835-6843.
16. Chen J., Tian R., Qiu M., Lu L., Zheng Y., Zhang Z. Trinorcucurbitane and cucurbitane triterpenoids from the roots of Momordica charantia. Phytochemistry 2008, 69:1043-1048.
17. Budrat P., Shotipruk A. Extraction of phenolic compounds from fruits of bitter melon (Momordica charantia) with subcritical water extraction and antioxidant activities of these extracts. Chiang Mai Journal of Science 2008, 35:123-130.
18. Jantan I., RafiI.A., Jalil J. Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants. Phytomedicine 2005, 12:88-92.
19. Anila L., Vijayalakshmi N.R. Beneficial effects of flavonoids from Sesamum indicum, Emblica officinalis and Momordica charantia. Phytotherapy Research 2000, 14:592-595.
20. Karunanayake E.H., Welihinda J., Sirimanne S.R., Sinnadorai G. Oral hypoglycaemic activity of some medicinal plants of Sri Lanka. Journal of Ethnopharmacology 1984, 11:223-231.
21. Chen Q., Chan L.L., Li E.T. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. The Journal of Nutrition 2003, 133:1088-1093.
22. Chaturvedi P., George S., Milinganyo M., Tripathi Y.B. Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytotherapy Research 2004, 18:954-956.
23. Welihinda J., Karunanayake E.H. Extra-pancreatic effects of Momordica charantia in rats. Journal of Ethnopharmacology 1986, 17:247-255.
24. Sathishsekar D., Subramanian S. Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biological and Pharmaceutical Bulletin 2005, 28:978-983.
25. Yibchok-anun S., Adisakwattana S., Yao C.Y., Sangvanich P., Roengsumran S., Hsu W.H. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biological and Pharmaceutical Bulletin 2006, 29:1126-1131.
26. Cummings E., Hundal H.S., Wackerhage H., Hope M., Belle M., Adeghate E., Singh J. Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Molecular and Cellular Biochemistry 2004, 261:99-104.
27. Roffey B.W., Atwal A.S., Johns T., Kubow S. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. Journal of Ethnopharmacology 2007, 112:77-84.
28. Miura T., Itoh C., Iwamoto N., Kato M., Kawai M., Park S.R., Suzuki I. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. Journal of Nutritional Science and Vitaminology (Tokyo) 2001, 47:340-344.
29. Shibib B.A., Khan L.A., Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: Depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. The Biochemical Journal 1993, 292(Pt 1):267-270.
30. Sarkar S., Pranava M., Marita R. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacological Research 1996, 33:1-4.
31. Day C., Cartwright T., Provost J., Bailey C.J. Hypoglycaemic effect of Momordica charantia extracts. Planta Medica 1990, 56:426-429.
32. Sekar D.S., Sivagnanam K., Subramanian S. Antidiabetic activity of Momordica charantia seeds on streptozotocin induced diabetic rats. Pharmazie 2005, 60:383-387.
33. Rathi S.S., Grover J.K., Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytotherapy Research 2002, 16:236-243.
34. Chuang C.Y., Hsu C., Chao C.Y., Wein Y.S., Kuo Y.H., Huang C.J. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L.). Journal of Biomedical Science 2006, 13:763-772.
35. Chao C.Y., Huang C.J. Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. Journal of Biomedical Science 2003, 10:782-791.
36. Ahmed I., Adeghate E., Sharma A.K., Pallot D.J., Singh J. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Research and Clinical Practice 1998, 40:145-151.
37. Welihinda J., Arvidson G., Gylfe E., Hellman B., Karlsson E. The insulin-releasing activity of the tropical plant Momordica charantia. Acta Biologica Et Medica Germanica 1982, 41:1229-1240.
38. Meir P., Yaniv Z. An in vitro study on the effect of Momordica charantia on glucose uptake and glucose metabolism in rats. Planta Medica 1985, 12-16.
39. Singh J., Adeghate E., Cummings E., Giannikipolous C., Sharma A.K., Ahmed I. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Molecular and Cellular Biochemistry 2004, 261:63-70.
40. Mahomoodally M.F., Fakim A.G., Subratty A.H. Momordica charantia extracts inhibit uptake of monosaccharide and amino acid across rat everted gut sacs in vitro. Biological and Pharmaceutical Bulletin 2004, 27:216-218.
41. Shetty A.K., Kumar G.S., Sambaiah K., Salimath P.V. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Foods for Human Nutrition 2005, 60:109-112.
42. Grover J.K., Vats V., Rathi S.S., Dawar R. Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. Journal of Ethnopharmacology 2001, 76:233-238.
43. Rathi S.S., Grover J.K., Vikrant V., Biswas N.R. Prevention of experimental diabetic cataract by Indian Ayurvedic plant extracts. Phytotherapy Research 2002, 16:774-777.
44. Srivastava Y., Venkatakrishna-Bhatt H., Verma Y., Prem A.S. Retardation of retinopathy by Momordica charantia L. (bitter gourd) fruit extract in alloxan diabetic rats. Indian Journal of Experimental Biology 1987, 25:571-572.
45. Srivastava Y., Venkatakrishna-Bhatt H., Verma Y. Effect of Momordica charantia Linn. pomous aqueous extract on cataractogenesis in murrin alloxan diabetics. Pharmacological Research Communications 1988, 20:201-209.
46. Senanayake G.V., Maruyama M., Sakono M., Fukuda N., Morishita T., Yukizaki C., Kawano M., Ohta H. The effects of bitter melon (Momordica charantia) extracts on serum and liver lipid parameters in hamsters fed cholesterol-free and cholesterol-enriched diets. Journal of Nutritional Science and Vitaminology (Tokyo) 2004, 50:253-257.
47. Jayasooriya A.P., Sakono M., Yukizaki C., Kawano M., Yamamoto K., Fukuda N. Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. Journal of Ethnopharmacology 2000, 72:331-336.
48. Chan L.L., Chen Q., Go A.G., Lam E.K., Li E.T. Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. The Journal of Nutrition 2005, 135:2517-2523.
49. Fernandes N.P., Lagishetty C.V., Panda V.S., Naik S.R. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complementary and Alternative Medicine 2007, 7:29.
50. Virdi J., Sivakami S., Shahani S., Suthar A.C., Banavalikar M.M., Biyani M.K. Antihyperglycemic effects of three extracts from Momordica charantia. Journal of Ethnopharmacology 2003, 88:107-111.
51. Senanayake G.V., Maruyama M., Shibuya K., Sakono M., Fukuda N., Morishita T., Yukizaki C., Kawano M., Ohta H. The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. Journal of Ethnopharmacology 2004, 91:257-262.
52. Raman A., Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996, 2:349-362.
53. Ng T.B., Wong C.M., Li W.W., Yeung H.W. A steryl glycoside fraction from Momordica charantia seeds with an inhibitory action on lipid metabolism in vitro. Biochemistry and Cell Biology 1986, 100:766-771.
54. Nerurkar P.V., Lee Y.K., Motosue M., Adeli K., Nerurkar V.R. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. The British Journal of Nutrition 2008, 100:751-759.
55. Chen Q., Li E.T. Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. The British Journal of Nutrition 2005, 93:747-754.
56. Shih C.C., Lin C.H., Lin W.L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Research and Clinical Practice 2008, 81:134-143.
57. Ojewole J.A., Adewole S.O., Olayiwola G. Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovascular Journal of South Africa 2006, 17:227-232.
58. Fletcher M.A., Caldwell K., Claflin A., Malinin T. Further characterization of a tumor cell growth inhibitor from the balsam pear. Federation American Society Experimental Biology 1980, 39:414. (Abstract).
59. Jilka C., Strifler B., Fortner G.W., Hays E.F., Takemoto D.J. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Research 1983, 43:5151-5155.
60. Nagasawa H., Watanabe K., Inatomi H. Effects of bitter melon (Momordica charantia L.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. The American Journal of Chinese Medicine 2002, 30:195-205.
61. Deep G., Dasgupta T., Rao A.R., Kale R.K. Cancer preventive potential of Momordica charantia L. against benzo(a)pyrene induced fore-stomach tumourigenesis in murine model system. Indian Journal of Experimental Biology 2004, 42:319-322.
62. Guevara A.P., Lim-Sylianco C., Dayrit F., Finch P. Antimutagens from Momordica charantia. Mutation Research 1990, 230:121-126.
63. Singh A., Singh S.P., Bamezai R. Momordica charantia (Bitter Gourd) peel, pulp, seed and whole fruit extract inhibits mouse skin papillomagenesis. Toxicology Letters 1998, 94:37-46.
64. Pongnikorn S., Fongmoon D., Kasinrerk W., Limtrakul P.N. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy. Journal of the Medical Association of Thailand 2003, 86:61-68.
65. Konishi T., Satsu H., Hatsugai Y., Aizawa K., Inakuma T., Nagata S., Sakuda S.H., Nagasawa H., Shimizu M. Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. British Journal of Pharmacology 2004, 143:379-387.
66. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:7735-7738.
67. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. The Journal of Biological Chemistry 1993, 268:14991-14997.
68. Larsen A.K., Escargueil A.E., Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacology and Therapeutics 2000, 85:217-229.
69. Limtrakul P., Khantamat O., Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemotherapy and Pharmacology 2004, 54:525-530.
70. Zhu B., Vemavarapu L., Thompson W.J., Strada S.J. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. Journal of Cellular Biochemistry 2005, 94:336-350.
71. Yasuda H., Hanai N., Kurata M., Yamada M. Cyclic GMP metabolism in relation to the regulation of cell growth in BALB/c3T3 cells. Experimental Cell Research 1978, 114:111-116.
72. Vesely D.L., Graves W.R., Lo T.M., Fletcher M.A., Levey G.S. Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abreviata). Biochemical and Biophysical Research Communications 1977, 77:1294-1299.
73. Claflin A.J., Vesely D.L., Hudson J.L., Bagwell C.B., Lehotay D.C., Lo T.M., Fletcher M.A., Block N.L., Levey G.S. Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata). Proceedings of the National Academy of Sciences of the United States of America 1978, 75:989-993.
74. Ng T.B., Liu W.K., Sze S.F., Yeung H.W. Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. General Pharmacology 1994, 25:75-77.
75. Yasui Y., Hosokawa M., Sahara T., Suzuki R., Ohgiya S., Kohno H., Tanaka T., Miyashita K. Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2005, 73:113-119.
76. Han C., Demetris A.J., Michalopoulos G.K., Zhan Q., Shelhamer J.H., Wu T. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology 2003, 38:167-177.
77. Nagamine M., Okumura T., Tanno S., Sawamukai M., Motomura W., Takahashi N., Kohgo Y. PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Science 2003, 94:338-343.
78. Sporn M.B., Suh N., Mangelsdorf D.J. Prospects for prevention and treatment of cancer with selective PPAR gamma modulators (SPARMs). Trends in Molecular Medicine 2001, 7:395-400.
79. Suh N., Wang Y., Williams C.R., Risingsong R., Gilmer T., Willson T.M., Sporn M.B. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Research 1999, 59:5671-5673.
80. Kobori M., Ohnishi-Kameyama M., Akimoto Y., Yukizaki C., Yoshida M. Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. Journal of Agricultural and Food Chemistry 2008, 56:10515-10520.
81. Kobori M., Nakayama H., Fukushima K., Ohnishi-Kameyama M., Ono H., Fukushima T., Akimoto Y., Masumoto S., Yukizaki C., Hoshi Y., Deguchi T., Yoshida M. Bitter gourd suppresses lipopolysaccharide-induced inflammatory responses. Journal of Agricultural and Food Chemistry 2008, 56:4004-4011.
82. Manabe M., Takenaka R., Nakasa T., Okinaka O. Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Bioscience, Biotechnology, and Biochemistry 2003, 67:2512-2517.
83. Ike K., Uchida Y., Nakamura T., Imai S. Induction of interferon-gamma (IFN-gamma) and T helper 1 (Th1) immune response by bitter gourd extract. The Journal of Veterinary Medical Science 2005, 67:521-524.
84. Jiratchariyakul W., Wiwat C., Vongsakul M., Somanabandhu A., Leelamanit W., Fujii I., Suwannaroj N., Ebizuka Y. HIV inhibitor from Thai bitter gourd. Planta Medica 2001, 67:350-353.
85. Leung S.O., Yeung H.W., Leung K.N. The immunosuppressive activities of two abortifacient proteins isolated from the seeds of bitter melon (Momordica charantia). Immunopharmacology 1987, 13:159-171.
86. Takemoto D.J., Kaplan S.A., Appleman M.M. Cyclic guanosine 3?,5?-monophosphate and phosphodiesterase activity in mitogen-stimulated human lymphocytes. Biochemical and Biophysical Research Communications 1979, 90:491-497.
87. Braca A., Siciliano T., D'Arrigo M., Germano M.P. Chemical composition and antimicrobial activity of Momordica charantia seed essential oil. Fitoterapia 2008, 79:123-125.
88. Beloin N., Gbeassor M., Akpagana K., Hudson J., de S.K., Koumaglo K., Arnason J.T. Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity. Journal of Ethnopharmacology 2005, 96:49-55.
89. Gurbuz I., Akyuz C., Yesilada E., Sener B. Anti-ulcerogenic effect of Momordica charantia L. fruits on various ulcer models in rats. Journal of Ethnopharmacology 2000, 71:77-82.
90. Dans A.M., Villarruz M.V., Jimeno C.A., Javelosa M.A., Chua J., Bautista R., Velez G.G. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. Journal of Clinical Epidemiology 2007, 60:554-559.
91. Basch E., Gabardi S., Ulbricht C. Bitter melon (Momordica charantia): A review of efficacy and safety. American Journal of Health-System Pharmacy 2003, 60:356-359.
92. Hulin A., Wavelet M., Desbordes J.M. Intoxication aigue par Momordica charantia (sorrossi). A propos de deux cas. La Semaine Des Hopitaux 1988, 64:2847-2848.
93. Platel K., Shurpalekar K.S., Srinivasan K. Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Nahrung 1993, 37:156-160.
94. Abd El Sattar El Batran S., El-Gengaihi S.E., El Shabrawy O.A. Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats. Journal of Ethnopharmacology 2006, 108:236-242.
95. (2009). Fruit of Momordica charantia.. http://www.omafra.gov.on.ca.
96. Akhtar M.S., Athar M.A., Yaqub M. Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits. Planta Medica 1981, 42:205-212.
97. Ali L., Khan A.K., Mamun M.I., Mosihuzzaman M., Nahar N., Nur-e-Alam M., Rokeya B. Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Medica 1993, 59:408-412.
98. Platel K., Srinivasan K. Effect of dietary intake of freeze dried bitter gourd (Momordica charantia) in streptozotocin induced diabetic rats. Nahrung 1995, 39:262-268.
99. Vikrant V., Grover J.K., Tandon N., Rathi S.S., Gupta N. Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. Journal of Ethnopharmacology 2001, 76:139-143.
100. Chaturvedi P. Role of Momordica charantia in maintaining the normal levels of lipids and glucose in diabetic rats fed a high-fat and low-carbohydrate diet. British Journal of Biomedical Science 2005, 62:124-126.
101. Shetty A.K., Suresh Kumar G., Salimath P.V. Bitter gourd (Momordica charantia) modulates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats. Molecular Nutrition and Food Research 2005, 49:791-796.
102. Oishi Y., Sakamoto T., Udagawa H., Taniguchi H., Kobayashi-Hattori K., Ozawa Y., Takita T. Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction. Bioscience, Biotechnology, and Biochemistry 2007, 71:735-740.
103. Han C., Hui Q., Wang Y. Hypoglycaemic activity of saponin fraction extracted from Momordica charantia in PEG/salt aqueous two-phase systems. Natural Product Research 2008, 22:1112-1119.
104. Singh N., Gupta M., Sirohi P., Varsha Effects of alcoholic extract of Momordica charantia (Linn.) whole fruit powder on the pancreatic islets of alloxan diabetic albino rats. Journal of Environmental Biology 2008, 29:101-106.
105. Sridhar M.G., Vinayagamoorthi R., Suyambunathan V.A., Bobby Z., Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. The British Journal of Nutrition 2008, 99:806-812.
106. Tan M.J., Ye J.M., Turner N., Hohnen-Behrens C., Ke C.Q., Tang C.P., Chen T., Weiss H.C., Gesing E.R., Rowland A., James D.E., Ye Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chemistry & Biology 2008, 15:263-273.
107. Patel J.C., Dhirawani M.K., Doshi J.C. Karella in the treatment of diabetes mellitus. Indian Journal of Medical Sciences 1968, 22:30-32.
108. Baldwa V.S., Bhandari C.M., Pangaria A., Goyal R.K. Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from plant sources. Upsala Jurnal of Medical Sciences 1977, 82:39-41.
109. Leatherdale B.A., Panesar R.K., Singh G., Atkins T.W., Bailey C.J., Bignell A.H. Improvement in glucose tolerance due to Momordica charantia (karela). British Medical Journal (Clinical Research Ed.) 1981, 282:1823-1824.
110. Akhtar M.S. Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. The Journal of the Pakistan Medical Association 1982, 32:106-107.
111. Welihinda J., Karunanayake E.H., SheriffM.H., Jayasinghe K.S. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. Journal of Ethnopharmacology 1986, 17:277-282.
112. Grover J.K., Gupta S.R. Hypoglycemic activity of seeds of Momordica charantia. European Journal of Pharmacology 1990, 183:1026-1027.
113. Srivastava Y., Venkatakhrishna-Bhatt H., Verma Y., Venkaiah K., Raval B.H. Anti-diabetic and adaptogenic properties of Momordica charantia extract: An experimental and clinical evaluation. Phytotherapy Research 1993, 7:285-289.
114. Ahmad N., Hassan M.R., Halder H., Bennoor K.S. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Medical Research Council Bulletin 1999, 25:11-13.
115. Rosales R., Fernando R. An inquiry to the hypoglycemic action of Momordica charantia among type 2 diabetic patients. Philippine Journal of Internal Medicine 2001, 39:213-216.
116. Marles R., Farnsworth N. Antidiabetic plants and their active constituents: An update. Phytomedicine 1997, 2:137-189.
117. Ng T.B., Chan W.Y., Yeung H.W. Proteins with abortifacient, ribosome inactivating, immunomodulatory, antitumor and anti-AIDS activities from Cucurbitaceae plants. General Pharmacology 1992, 23:579-590.
118. Tam P.P., Law L.K., Yeung H.W. Effects of alpha-momorcharin on preimplantation development in the mouse. Journal of Reproduction and Fertility 1984, 71:33-38.
119. Chan W.Y., Tam P.P., Yeung H.W. The termination of early pregnancy in the mouse by beta-momorcharin. Contraception 1984, 29:91-100.
120. Dixit V.P., Khanna P., Bhargava S.K. Effects of Momordica charantia L. fruit extract on the testicular function of dog. Planta Medica 1978, 34:280-286.
121. Stepka W., Wilson K.E., Madge G.E. Anti-fertility investigation on Momordica. Lloydia 1974, 37:645.
122. Sharma V.N., Sogani R.K., Arora R.B. Some observations on hypoglycaemic activity of Momordica charantia. The Indian Journal of Medical Research 1960, 48:471-477.
123. Tennekoon K.H., Jeevathayaparan S., Angunawala P., Karunanayake E.H., Jayasinghe K.S. Effect of Momordica charantia on key hepatic enzymes. Journal of Ethnopharmacology 1994, 44:93-97.